Two New p-Tau217 Blood Tests Join a Crowded Field
C2N’s PrecivityAD2 and ALZpath Inc.’s p-tau217 immunoassay identify people with AD with good accuracy.
ALL NEWS
6537 RESULTS
Sort By:
- Most Recent
- Most Commented
Plasma p-Tau-217 Assays Work Well, But No Home Run for Diagnosis
For a diagnostic test, specificity and sensitivity fall a little shy. Using two cut points might solve the problem.
Can a Fatty Acid Explain Sex Differences in Parkinson’s?
Adding palmitate makes an estrogen receptor linger at the synapse, curbing α-synuclein aggregation, motor deficits, and faulty memory. In mice.
New Alzheimer’s Diagnostic Criteria Remain ‘Research Only’
This clarification comes after geriatricians argued that diagnosing AD in people without symptoms is premature, and the NIH pulled its name.
Do APOE4’s Lipid Shenanigans Trigger Tauopathy?
Faulty lipid metabolism is being blamed for supercharging tau phosphorylation. Restoring lipid efflux protects the mouse brain.
At the Core of Microglial Signaling: γ-Secretase
Signaling within microglia requires dozens of substrates of γ-secretase. Without the enzyme, the cells barely react to plaques in mice.
Gauging Cognition From Your Couch? The Digital Age Has Arrived.
Smartphone- and web-based cognitive tasks detected amyloid positivity, early Alzheimer’s, better than in-person tests. Some are being used in clinical trials.
Gotta Get Rid of It All: Total Plaque Clearance Key for Clinical Benefit
In amyloid immunotherapy trials to date, abolishing plaque leads to better outcomes months later. Cognitive benefits lag behind amyloid removal.
Second-Generation γ-Secretase Modulator Heads to Phase 2
In a Phase 1 trial of Roche’s RG6289, both plasma and CSF Aβ37 climbed, while Aβ42 fell.
Patricidal Protein? Aβ42 said to Inhibit Its Parent, γ-Secretase
At high concentrations, Aβ42 gums up the protease’s active site. A new theory explains how γ-secretase modulators work. One is en route to Phase 2.
In Progressive Supranuclear Palsy, Risk Loci Converge on Oligodendrocytes
The largest genome-wide association study for PSP tied six risk loci to the tauopathy, including one new locus near the complement C4A gene.
Unlocking Blood-Brain Barrier Boosts Immunotherapy Efficacy, Lowers ARIA
Roche’s “brain shuttle” antibody, trontinemab, cleared plaque in Phase 1 with little ARIA, highlighting that bypassing vascular amyloid could be the key.
After Long Wait, Aβ Oligomer Detangler Poised for Phase 2
Phase 1b results tease that the small molecule PRI-002 might curb cognitive decline. Phase 2 is slated for early 2024.
Moving Forward: RNA-Targeted Attempts at Taking Down Tau, APP
In early phase trials, therapy lowering tau translation hinted at cognitive benefit, while going after APP lowered its fragments and Aβ peptides.
Treat Before ‘Aβ Bothers Tau,’ Scientists Say at CTAD
At trials conference, multiple amyloid immunotherapy programs reported greatest cognitive benefits for people whose tau tangle deposition has only just begun.
Current Filters
No filters selected